Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations

Nuclear Medicine Communications

Volumn 30, Issue 2, 2009, Pages 176-182

  Grassi, Elisa ^a,b   Sghedoni, Roberto ^a   Asti, Mattia ^a   Fioroni, Federica ^a   Salvo, Diana ^a   Borasi, Giovanni ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b Arc Santa Maria Nuova   (Italy)

Author keywords

90Y; Beta radiation; Finger dose; Radiation exposure; Skin exposure

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO PHENYLALANYL 1 TYROSYL 3 OCTREOTIDE Y 90; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 90Y OCTREOTIDE, DOTA TYR(3); 90Y-OCTREOTIDE, DOTA-TYR(3)-; DRUG DERIVATIVE; OCTREOTIDE;

ARTICLE; CLINICAL PRACTICE; DOSIMETER; DOSIMETRY; HUMAN; PROTECTIVE CLOTHING; RADIATION ABSORPTION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RADIATION PROTECTION; CHEMISTRY; ITALY; METHODOLOGY; NUCLEAR MEDICINE; OCCUPATIONAL EXPOSURE; RADIOMETRY;

CHEMISTRY; HUMANS; ITALY; NUCLEAR MEDICINE; OCCUPATIONAL EXPOSURE; OCTREOTIDE; RADIATION DOSAGE; RADIATION PROTECTION; RADIOMETRY; RADIOPHARMACEUTICALS;

EID: 58549092837     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328318effb     Document Type: Article

References (26)

1. Delacroix D, Guerre JP, Leblanc P, Hickman C. Radionuclide and radiation protection data handbook 2002, 2nd edition. Radiât Prot Dosimetry 2002; 98:1-168.
2. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006; 47:1467-1475.
3. Kwekkeboom DJ1 Muelter-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. An overview of the peptide receptor radionuclide therapy with 3 different radiolabeled somalostatin analogs. J Nucl Med 2005; 46 (Suppl 1):62S-66S.
4. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32:148-155.
5. 90Y-DOTATOC. J Nucl Med 2002; 43:610-616.
6. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12:941-945.
7. 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005; 46:1310-1316.
8. Rimpler A, Barth I. Beta radiation exposure of medical staff and implications for extremity dose monitoring. Radiat Prot Dosimetry 2007; 125:335-339.
9. ICRP Publication 103, The 2007 Recommendations of the International Commission on Radiological Protection, Annals of the ICRP 2008, 37/2-4, par. 5.10.
10. Chapter II, Limitation of doses. In: European Directive EURATOM 96/29 05/13/1996, Luxemburg: European Commission-Radiation Protection Division, 1996. pp. 7-8.
11. Moscovitch M. Personnel dosimetry using LiF:Mg, Cu, P. Radiat Prot Dosimetry 1999; 85:49-56.
12. Niewiadomski T. 25 years of TL dosimetry at the Institute of Nuclear Physics, Krakow. Radiat Prot Dosimetry 1996; 65:1-6.
13. Boschung M, Homsy A, Joneja OP, Chawla R. Characterisation of MCP-7 s material for use as a beta extremity dosemeter. Radiat Prot Dosimetry 2000; 92:313-318.
14. Bilski P, Olko P, Burgkhardt B, Piesch E. Ultra-thin LiF:Mg, Cu, P detectors for beta dosimetry. Radiat Meas 1995; 24:439-443.
15. 90Y-conjugates: risks and safety. Eur J Nucl Med Mol Imaging 2006; 33:1321-1327.
16. De Jong M, Bakker WH, Krenning EP, Breeman WAP, Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24:368-371.
17. Decreto Legislative 26 Maggio 2000, n. 187: actuation of the Council Directive 97/43/EURATOM in the Italian regulation.
18. Lancelot S, Quillet B, Sigrist S, Bourelly M, Waultier S, Mundler O, et al. Exposure of medical personnel to radiation during radionuclide therapy practices. Nucl Med Commun 2008; 29:405-410.
19. Covens P, Berus D, Buls N, Clerinx P, Vanhavere F. Personal dose monitoring in hospitals: global assessment, critical applications and future needs. Radiat Prof Dosimetry 2007; 124:250-259.
20. Saether HK, Davidson TM, Widmark A, Wohni T. Measurements of finger doses in X-ray guided surgery, nuclear medicine and research. Radiat Prof Dosimetry 2005; 113:392-395.
21. Decreto Legislative 26 Maggio 2000, n. 241: actuation of the Council Directive 96/29/EURATOM in the Italian regulation.
22. Thomas CC. Radiobiology. Chapter XVIII. In: Johns HE, Cunningham JR, editors. The physics of radiology. Illinois: Springfield; 1983. pp. 678.
23. Chèrel M, Davodeau F, Kraeber-Bodèrè F, Chatal JF. Current status and perspectives in alpha radioimmunotherapy. Q J Nucl Med Mol Imaging 2006; 50:322-329.
24. Nilsson S, Larsen RH, Fossa SD, Baltedskard L, Borch KW, Westlin JE, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005; 11:4451-4459.
25. 227Th-p-benzyl-DOTA-rituximab for low-dose rate α-particle radioimmunotherapy. Nucl Med Biol 2006; 33:271-279.
26. 177Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol 2007; 34:185-193.